Prostate Cancer

Molecular tumor profiling is rapidly driving personalized medicine within oncology. The value of identifying a targetable mutation using next-generation sequencing for available therapies or clinical trials cannot be underestimated. Herein, we review essential considerations in the initial assessment, specialty referral, and sequencing of treatment for advanced prostate cancer with an identified actionable mutation.

Reviewers Commentary: This article adds to the growing body of literature on the role of PARP inhibitors in tumors with DNA repair defects.

Several new indications were approved by the FDA in March, including blinatumomab (Blincyto) for MRD+ ALL, brentuximab vedotin (Adcetris) for Hodgkin lymphoma, and a 4-week nivolumab (Opdivo) dosing schedule across several indications. Here’s a look back on the FDA happenings for the month of March 2018.

Prostate Cancer

Based on data from the phase III PROSPER trial, a supplemental new drug application for enzalutamide for the treatment of men with nonmetastatic castration-resistant prostate cancer has been granted a priority review by the FDA, according to Pfizer and Astellas, the companies developing the antiandrogen agent.

Lung Cancer

<em>Targeted Therapies in Oncology</em>, an oncology resource that provides oncology professionals with cutting-edge research, data, and treatment strategies surrounding molecular and immune system targets, welcomes&nbsp;Arjun V. Balar, MD,&nbsp;as its editor-in-chief.

Bridget F. Koontz, MD, associate professor of radiation oncology, Duke Cancer Institute, discusses a single-arm, phase II trial of 6 months of concurrent androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.